ID   ND-1
AC   CVCL_4781
SY   ND1
DR   BTO; BTO:0001052
DR   BioSample; SAMN03151638
DR   cancercelllines; CVCL_4781
DR   Wikidata; Q54908299
RX   CelloPub=CLPUB00698;
RX   PubMed=1279221;
RX   PubMed=11304728;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a DU145 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a patient of unknown age with a primary prostate adenocarcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00244.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (PubMed=11304728).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (PubMed=11304728).
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=11304728
ST   Amelogenin: X,Y
ST   D13S317: 11,12,14
ST   D18S51: 12
ST   D21S11: 30,33
ST   D3S1358: 15,16
ST   D5S818: 10,14
ST   D7S820: 7,10,11
ST   D8S1179: 13,14
ST   FGA: 22
ST   vWA: 17
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0105 ! DU145
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
//
RX   PubMed=1279221; DOI=10.1016/S0022-5347(17)36978-1;
RA   Narayan P., Dahiya R.;
RT   "Establishment and characterization of a human primary prostatic
RT   adenocarcinoma cell line (ND-1).";
RL   J. Urol. 148:1600-1604(1992).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//